With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
The target demographic will be those between the ages of 30 and 65 years
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Previously, the use of the drug was limited to patients requiring hospitalization
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Subscribe To Our Newsletter & Stay Updated
